Amgen, Bristol Myers Briggs and Vertex Pharmaceuticals were among the investors that brought the gene therapy developer’s overall funding to over $164m.

Obsidian Therapeutics, a US-based engineered cell and gene therapy biotechnology developer, has completed a $115m series B round that included pharmaceutical companies Amgen, Bristol Myers Squibb and Vertex Pharmaceuticals.

Venture capital fund The Column Group led the round, which was filled out by RA Capital Management, Surveyor Capital, Deep Track Capital, Cowen Healthcare Investments, Logos Capital, Atlas Venture, Samsara Biocapital, Pivotal BioVenture Partners, Vertex Ventures and Soleus Capital, while Amgen invested through corporate VC arm Amgen Ventures.

Founded in 2015,…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.
Email LinkedIn